Cargando…

Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response

Detalles Bibliográficos
Autores principales:	Elliott, Kerryn, Nilsson, Jonas, Van den Eynden, Jimmy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553762/ https://www.ncbi.nlm.nih.gov/pubmed/34711802 http://dx.doi.org/10.1038/s41392-021-00789-9

Ejemplares similares

New insights into pathogen-mediated modulation of host RNA splicing
por: Gao, Chuyun, et al.
Publicado: (2022)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Lack of detectable neoantigen depletion signals in the untreated cancer genome
por: Van den Eynden, Jimmy, et al.
Publicado: (2019)

Immune modulation of HLA-G dimer in maternal-fetal interface
por: Kuroki, Kimiko, et al.
Publicado: (2007)

Puzzling mRNA: Alternative splicing fine-tunes specificity and function
por: Häfner, Sophia Julia
Publicado: (2019)

Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity
por: Schijns, Virgil, et al.
Publicado: (2020)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy
por: Nüse, Björn, et al.
Publicado: (2022)

Dendrimer nanocarriers drug action: perspective for neuronal pharmacology
por: Vidal, Felipe, et al.
Publicado: (2015)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

All the small things: How virus‐like particles and liposomes modulate allergic immune responses
por: Kratzer, Bernhard, et al.
Publicado: (2019)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Identifying neoantigens for use in immunotherapy
por: Hutchison, Sharon, et al.
Publicado: (2018)

The Role of Neoantigens in Cancer Immunotherapy
por: Zhu, Yueting, et al.
Publicado: (2021)

Targeting neoantigens for cancer immunotherapy
por: Zhao, Xuan, et al.
Publicado: (2021)

EDS1 modules as two-tiered receptor complexes for TIR-catalyzed signaling molecules to activate plant immunity
por: Li, Jia, et al.
Publicado: (2022)

New strategy for cancer immunotherapy: using live engineered bacteria for metabolic modulation
por: Li, Tong, et al.
Publicado: (2021)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
por: Efremova, Mirjana, et al.
Publicado: (2017)

MHC-II neoantigens shape tumor immunity and response to immunotherapy
por: Alspach, Elise, et al.
Publicado: (2019)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

The incredible complexity of RNA splicing
por: Robert, Christelle, et al.
Publicado: (2016)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Neoantigen vaccine: an emerging tumor immunotherapy
por: Peng, Miao, et al.
Publicado: (2019)

Mutation-Derived Neoantigens for Cancer Immunotherapy
por: Castle, John C., et al.
Publicado: (2019)

Progress in Neoantigen Targeted Cancer Immunotherapies
por: Han, Xue-Jiao, et al.
Publicado: (2020)

Neoantigens and their potential applications in tumor immunotherapy
por: Fang, Xianzhu, et al.
Publicado: (2022)

Cancer neoantigens as potential targets for immunotherapy
por: Ma, Weijie, et al.
Publicado: (2021)

The Value of Microbes in Cancer Neoantigen Immunotherapy
por: Tian, Junrui, et al.
Publicado: (2023)

Interactome analysis brings splicing into focus
por: Dominguez, Daniel, et al.
Publicado: (2015)

NeoSplice: a bioinformatics method for prediction of splice variant neoantigens
por: Chai, Shengjie, et al.
Publicado: (2022)

Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature
por: Fredriksson, Nils Johan, et al.
Publicado: (2017)

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking
por: Fallahzadeh-Mamaghami, Vahid, et al.
Publicado: (2023)

Deletional tolerance prevents AQP4‐directed autoimmunity in mice
por: Vogel, Anna‐Lena, et al.
Publicado: (2017)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Understanding and repurposing CRISPR-mediated alternative splicing
por: Smith, Jordan L., et al.
Publicado: (2018)

Deep Learning Deepens the Analysis of Alternative Splicing
por: Zou, Xudong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_je2qk0qmnteav35fi0ru7qluru